Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's Oncology Drug Strategy Emphasizes Comprehensive Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Executives emphasized the role of "comprehensive diagnostics" in its plan to establish a dominant position in immuno-oncology drugs at this years' American Society of Clinical Oncology annual meeting.

You may also be interested in...



Roche Wins 'Complimentary' Diagnostic Approval With Bladder Cancer Immune Therapy

FDA approved Roche's Ventana PD-L1 assay to help identify patients more likely to respond to its Tecentriq drug for bladder cancer. It's approved as a helpful tool, rather than required test, with the drug, but the assay is part of a growing class of diagnostics that are likely to play an important supporting role in a promising and high-growth branch of oncology.

In Case You Missed It: Top 10 "Gray Sheet" Stories In June

"The Gray Sheet" offerings that captured the most Web traffic last month centered on device recall trends, combination products, exclusive interviews with two FDA officials and our new Device Week podcast.

Companion Diagnostics Come Of Age

The US companion diagnostics sector is predicted to grow from $1.6 billion to $6.2 billion between 2015 and 2021, a CAGR of 25.3%, outpacing the IVD market growth fivefold. This rapid growth will be driven by the development of new targeted pharmaceutical products and moves by the FDA to quickly approve new treatments and diagnostics together.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT033986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel